New Quaternary Ammonium Salts for use in Drug Manufacture

Project Information

QuatSalts

Grant agreement ID: 690882

DOI

10.3030/690882

Project closed

EC signature date 3 November 2015

Start date 1 March 2016

End date 29 February 2020

Funded under

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Total cost

€ 774 000,00

EU contribution

€ 774 000,00

Coordinated by

UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II
Italy

Periodic Reporting for period 2 - QuatSalts (New Quaternary Ammonium Salts for use in Drug Manufacture)

Reporting period: 2018-03-01 to 2020-02-29

Summary of the context and overall objectives of the project

The problem being addressed: The ability to develop more environmentally friendly ways of manufacturing pharmaceuticals


Why it's important for society: It is important so that pharmaceuticals can still be made, but with less harmful chemicals being employed in their manufacture which can have a deleterious impact on the environment


What are the overall objectives: To develop, test and implement new catalysts which enable the environmentally friendly manufacture of drugs

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

We have been involved in the design and synthesis of new families of ammonium salts organocatalysts (WP1) and peptide-based catalysts (WP2). We have also started a programme of evaluation of these catalysts.
So far we have successful made a number of these catalysts and they have given some promising results

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

The catalysts which we are developing will advance the state of the art insofar as they will avoid the use of precious metals. They will also enable selectivity which is enhanced compared with other catalysts currently available on the market. In terms of the impact, the availability of these catalysts will enable new job creation, securing of existing jobs in Europe (which are under increasing pressure from lower wage economies in the pharmachem sector like India and China. In addition it will lead to new intellectual property which can be patented and might be the basis of formation of new companies.

image for publication